← FDA DRUG APPROVALS

FDA ANDA · ANDA077219

IRINOTECAN HYDROCHLORIDE

Sponsor: CIPLA LTD

APPLICATION
ANDA077219
TYPE
ANDA
ORIGINAL APPROVAL
2008-02-20
LATEST ACTION
2023-03-15
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

IRINOTECAN HYDROCHLORIDEDiscontinued
IRINOTECAN HYDROCHLORIDE 100MG/5ML (20MG/ML) · INJECTABLE · INJECTION
IRINOTECAN HYDROCHLORIDEDiscontinued
IRINOTECAN HYDROCHLORIDE 40MG/2ML (20MG/ML) · INJECTABLE · INJECTION

Approval history

2023-03-15Labeling · Supplement 12 · standardAP
2020-06-19Labeling · Supplement 10 · standardAP
2020-06-19Labeling · Supplement 11 · standardAP
2016-10-07Labeling · Supplement 9 · standardAP
2016-10-07Labeling · Supplement 7 · standardAP
2013-04-29Labeling · Supplement 4 · standardAP
2013-01-24Labeling · Supplement 2AP
2008-02-20OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →